Oğulcan Boz

Oğulcan Boz

Auto-generated profile, based on publicly available information

Oğulcan Boz

Department of Endocrinology and Metabolism, Etlik City Hospital, Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
GTGozde Tahtaci
Gozde Tahtaci
NGNazan Günel
Nazan Günel
ASAysu Sadi̇oĞlu
Aysu Sadi̇oĞlu
NANalan Akyurek
Nalan Akyurek
OBOğulcan Boz
Oğulcan Boz
AÜAytuğ Üner
Aytuğ Üner
Background/aim: This study aimed to evaluate the expression of lymphocyte activation gene-3 (LAG-3) and its relationship with programmed cell death ligand-1 (PD-L1) in triple-negative breast cancer (TNBC). Materials and methods: LAG-3 and PD-L1 was evaluated in tumor-infiltrating lymphocytes (TILs) using immunohistochemistry (IHC). The chi-square test was used to estimate the associations between LAG-3, PD-L1 and clinicopathological characteristics. Correlation between LAG-3 stromal TIL (sTIL), LAG-3 intraepitelial TIL (iTIL) and PD-L1 was assessed with using the Spearman's correlation coefficient. Survival analysis was performed using the Kaplan-Meier method. Results: The percentages of LAG-3 sTIL+, LAG-3 iTIL+, PD-L1+ tumor cells and PD-L1+ inflammatory cells were 52%, 42%, 14% and 70%, respectively. A strong positive correlation between LAG-3 sTIL and LAG-3 iTIL (r = 0.874, p < 0.001) and a moderate positive correlation between LAG-3 sTIL and PD-L1 (r = 0.584, p < 0.001) were found. LAG-3 and PD-L1 status did not significantly affect overall survival (OS) (HR: 0.56 (95% CI: 0.15-2.11) (p = 0.397), HR: 2.70 (95% CI: 0.56-13.02) (p = 0.215), respectively). Conclusion: High levels of LAG-3 and PD-L1 expression were detected in patients with TNBC. Although their contribution to survival could not be determined, the high expression rates of PD-L1 and LAG-3 may help identify the subgroup of TNBC that would benefit from immunotherapy.

12 December 2025 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
NANai̇m Ata
Nai̇m Ata
BUBekir Ucan
Bekir Ucan
HDHali̇l Durantaş
Hali̇l Durantaş
OBOğulcan Boz
Oğulcan Boz
MSMustafa - Sahin
Mustafa - Sahin
MKMuhammed Kizilgül
Muhammed Kizilgül
Background/aim: Although low phosphorus (P) concentrations are a recognized feature of primary hyperparathyroidism (PHPT), they are not among the diagnostic or surgical criteria. The present study evaluates the association between serum phosphorus levels and clinical outcomes in PHPT patients. Materials and methods: A search of the Turkish Ministry of Health’s National Electronic Database was conducted using ICD-10 diagnostic codes and laboratory data to identify PHPT cases within the Turkish population from 2017 to 2022. Results: The records of a total of 113,330 PHPT patients (77.5% female; mean age 58.9 ± 15.6 years) were analyzed, revealing a mean serum phosphorus level of 3.24 ± 0.79 mg/dL. Patients with nephrolithiasis, vitamin D <20 μg/L, and calcium ≥11.4 mg/dL had significantly lower phosphorus levels (p<0.0001). Hypophosphatemia (HypoP) (P < 2.5 mg/dL) was present in 14.3% of patients and was associated with higher parathyroid hormone, calcium, and alkaline phosphatase levels, and lower vitamin D levels (all p < 0.0001). HypoP independently increased the risk of kidney stone formation (OR = 1.53; 95% CI 1.46–1.61). Conclusion: HypoPis associated with more severe biochemical abnormalities and a greater prevalence of nephrolithiasis in PHPT. In regions where vitamin D deficiency is common, low phosphorus levels may indicate more severe diseases, and so routine phosphorus monitoring should be considered as part of PHPT management.

3 March 2025 in Endocrinology Research and Practice
Verified
Journal Article
Open access
BHBurcak Cavnar Helvaci
Burcak Cavnar Helvaci
SHSema Hepsen
Sema Hepsen
MKMuhammed Kızılgul
Muhammed Kızılgul
OBOğulcan Boz
Oğulcan Boz
HDHalil Durantas
Halil Durantas
ECErman Cakal
Erman Cakal
Objective: Acromegaly is a rare endocrine disorder marked by elevated levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), which frequently result in insulin resistance and diabetes mellitus (DM). Sodium-glucose co-transporter 2 inhibitors (SGLT2is) have demonstrated potential in managing DM, but their impact on IGF-1 levels in patients with acromegaly and DM remains not fully understood. Methods: This study aimed to investigate the effects of SGLT2is on IGF-1 levels in patients with acron megaly and DM. Fourteen adult patients with acromegaly and DM treated with SGLT2is were included in this single-center, retrospective clinical trial. Plasma glucose, HbA1c, creatinine, GH, and IGF-1 lev nels were measured before and at 6 and 12 months after initiating SGLT2i treatment. Statistical analy ses were performed to assess changes in these parameters over time. Results: No statistically significant differences were observed in plasma glucose, HbA1c, creatinine, GH, and IGF-1 levels in the overall patient group at 6 and 12 months of follow-up. However, a signifi cant decrease in IGF-1 levels was noted at both time points in patients with IGF-1 levels <1.5 times the upper limit of normal. No correlations were found between changes in metabolic parameters and IGF-I levels. Conclusion: Our findings suggest that SGLT2is may have a role in modulating IGF-1 levels in a subset of patients with acromegaly, particularly those with relatively higher IGF-1 levels. This study repre sents the first investigation into the effects of SGLT2is on IGF-1 levels in patients with acromegaly and DM, providing a foundation for future research in this area. Further studies are needed to confirm these results and elucidate the underlying mechanisms. Cite this article as: Cavnar Helvaci B, Hepsen S, Kızılgul M, Boz O, Durantas H, Cakal E. Effect of sodium-glucose co-transporter 2 inhibitors on insulin-like growth factor 1 level in diabetic acromegaly patients. Endocrinol Res Pract. 2025;29(2):107-112.

16 June 2026 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
ÜGÜmran Gül
Ümran Gül
BUBekir Ucan
Bekir Ucan
HBHayri̇ Bostan
Hayri̇ Bostan
HDHakan Düğer
Hakan Düğer
HKHüseyin Hayri Kertmen
Hüseyin Hayri Kertmen
MKMuhammed Kizilgül
Muhammed Kizilgül
Background/aim: This study aimed to evaluate the demographic, clinical, and hormonal characteristics; comorbidities; surgical pathology; treatment modalities; and long-term clinical outcomes of patients diagnosed with and managed for acromegaly at our tertiary referral center over a 15-year period. Materials and methods: Between 2010 and 2024, 247 patients with acromegaly were evaluated. Diagnosis and biochemical remission were determined according to the 2024 Acromegaly Consensus Criteria. Results: The median follow-up duration was 8 years (IQR: 3–14). At the time of diagnosis, the most frequent pituitary hormone deficiency was secondary adrenal insufficiency, present in 17.8% of patients. The most common comorbidities were hypertension (HT, 42.1%) and diabetes mellitus (DM, 30.8%). At the time of diagnosis, macroadenomas were present in 153 of 193 patients (79.3%), and, according to the Knosp classification, 28.6% of tumors were grade 4. A total of 218 patients underwent surgical intervention; 86 (39.4%) achieved postoperative cure without the need for adjuvant medical therapy or radiotherapy. Postoperatively, one or more anterior pituitary hormone deficiencies were found in 34 patients (22.8%), with central hypothyroidism being the most common (52.9%). Patients who achieved biochemical remission were significantly older (p = 0.003), had a higher prevalence of HT and DM (both p < 0.05), and were more likely to exhibit positive growth hormone (GH) immunostaining (p = 0.017). In contrast, those who did not achieve remission were more likely to have higher Knosp grades (3–4) (p = 0.002). Conclusions: In this study, a favorable prognosis was associated with older age at diagnosis, lower baseline GH levels, positive GH immunostaining, smaller tumor size, and lower Knosp grade, underscoring the prognostic value of both biochemical and anatomical parameters. Further studies are warranted to refine prognostic markers and establish standardized treatment algorithms to improve long-term outcomes in acromegaly.